JUNE 18, 2019
Study Presented at American Diabetes Association 79th Scientific Sessions Observed Substantially Less Hypoglycemia With Use of Glytec’s Technology
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s ® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
|Outcomes||Glytec eGMS®||Usual Care||Difference in Rate||p Value|
|% BGs <40 mg/dL||0.02%||0.44%||95.5% less with eGMS®||<0.01|
|% BGs <54 mg/dL||0.08%||1.02%||92.2% less with eGMS®||<0.01|
|% BGs <70 mg/dL||0.32%||2.44%||86.9% less with eGMS®||<0.01|
|% BGs <250 mg/dL||7.00%||10.10%||30.7% less with eGMS®||<0.01|
|% BGs 70-180 mg/dL||69.80%||66.34%||5.2% more with eGMS®||<0.01|
With a continual influx of new resident physicians from both and , systemization with Glytec’s technology has proven a valuable teaching mechanism, especially given Grady Hospital is the primary destination for many of Georgia’s most complex cases.
“This study demonstrated that personalization of insulin therapy with an evidence-based system’s approach is superior to usual care in improving glycemic control for our critical care patients,” said , Professor of Medicine in the Division of Endocrinology and Metabolism at Emory University School of Medicine and Chief of Diabetes and Endocrinology at Grady Hospital.
Dr. Jordan Messler, Executive Director of Quality Initiatives at Glytec, adds: “We are pleased to see that Grady Hospital continues to experience clinical excellence with eGMS® and continues to see outcomes improvements. The results of this new study, which reflect on data from the initial two-year period post-implementation, are consistent with the results of an published January 2018 in the Journal of Diabetes Science and Technology, which looked at data over the first four months post-implementation.”
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System® is the only FDA-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.